Several thousand children get RS virus every year and there have been limited measures. The hope is that the drug can be given out to infants as early as this autumn.
Region Stockholm is awaiting an investigation from the NT Council (Council for New Therapies) It is there that it will be investigated whether the drug is cost-effective and, if so, what the price tag will end up at. And who will receive the drug first is also not clear, says Åsa Derolf of Region Stockholm.